Literature DB >> 23201161

Association between abnormal myocardial fatty acid metabolism and cardiac-derived death among patients undergoing hemodialysis: results from a cohort study in Japan.

Masao Moroi1, Nagara Tamaki, Masato Nishimura, Kazuo Haze, Tsunehiko Nishimura, Eiji Kusano, Takashi Akiba, Tokuichiro Sugimoto, Hiroki Hase, Kazuhiro Hara, Tomoaki Nakata, Shinichiro Kumita, Yoji Nagai, Akiyoshi Hashimoto, Mitsuru Momose, Keiko Miyakoda, Naoyuki Hasebe, Kenjiro Kikuchi.   

Abstract

BACKGROUND: Detecting myocardial ischemia in hemodialysis patients is crucial given the high incidence of silent ischemia and the high cardiovascular mortality rates. Abnormal myocardial fatty acid metabolism as determined by imaging with (123)I-labeled BMIPP (β-methyl iodophenyl-pentadecanoic acid) might be associated with cardiac-derived death in hemodialysis patients. STUDY
DESIGN: Prospective observational study. SETTING & PARTICIPANTS: Asymptomatic hemodialysis patients with one or more cardiovascular risk factors, but without known coronary artery disease, were followed up for 3 years at 48 Japanese hospitals (406 men, 271 women; mean age, 64 years). PREDICTOR: Baseline BMIPP summed scores semiquantified using a 17-segment 5-point system (normal, 0; absent, 4). OUTCOMES: Cardiac-derived death, including cardiac and sudden death. MEASUREMENTS: HRs were estimated using a Cox model for associations between BMIPP summed scores and cardiac-derived death, adjusting for potential confounders of age, sex, body mass index, dialysis duration, and cardiovascular risk factors.
RESULTS: Rates of all-cause mortality and cardiac-derived death were 18.5% and 6.8%, respectively. Cardiac-derived death (acute myocardial infarction [n = 10], congestive heart failure [n = 13], arrhythmia [n = 2], valvular heart disease [n = 1], and sudden death [n = 20]) accounted for 36.8% of all-cause deaths. Cardiac-derived death (n = 46) was associated with age, history of heart failure, and BMIPP summed scores of 4 or higher (HR, 2.9; P < 0.001). Three-year cardiac-derived death-free survival rates were 95.7%, 90.6%, and 78.8% when BMIPP summed scores were 3 or lower, 4-8, and 9 or higher, respectively. BMIPP summed score also was a predictor of all-cause death (HR, 1.6; P = 0.009). LIMITATIONS: Sudden death of unknown cause was considered to have been cardiac derived, although a coronary origin was not confirmed.
CONCLUSIONS: Abnormal myocardial fatty acid metabolism is associated with cardiac-derived death in hemodialysis patients. BMIPP single-proton emission computed tomography appears clinically useful for predicting cardiac-derived death in this population.
Copyright © 2013 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23201161     DOI: 10.1053/j.ajkd.2012.09.017

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  16 in total

Review 1.  Recent advances in metabolic imaging.

Authors:  Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

Review 2.  Mineral metabolism and cardiovascular disease in CKD.

Authors:  Hideki Fujii; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2017-01-06       Impact factor: 2.801

3.  Platelet reactivity in patients with chronic kidney disease and hemodialysis.

Authors:  Philipp Mourikis; Carolin Helten; Lisa Dannenberg; Thomas Hohlfeld; Johannes Stegbauer; Tobias Petzold; Bodo Levkau; Tobias Zeus; Malte Kelm; Amin Polzin
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

Review 4.  Current status of nuclear cardiology in Japan: Ongoing efforts to improve clinical standards and to establish evidence.

Authors:  Keiichiro Yoshinaga; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2015-04-22       Impact factor: 5.952

5.  The FRAX ® as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up study.

Authors:  Toshihide Hayashi; Nobuhiko Joki; Yuri Tanaka; Masaki Iwasaki; Shun Kubo; Takasuke Asakawa; Ai Matsukane; Yasunori Takahashi; Yoshihiko Imamura; Koichi Hirahata; Hiroki Hase
Journal:  J Bone Miner Metab       Date:  2015-02-18       Impact factor: 2.626

Review 6.  Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.

Authors:  Keiichiro Yoshinaga; Masanao Naya; Tohru Shiga; Eriko Suzuki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

7.  Thallium-201 washout rate of stress myocardial perfusion imaging as a predictor of mortality in diabetic kidney disease patients initiating hemodialysis: an observational, follow-up study.

Authors:  Toshihide Hayashi; Nobuhiko Joki; Yuri Tanaka; Masaki Iwasaki; Shun Kubo; Ai Matsukane; Yasunori Takahashi; Yoshihiko Imamura; Koichi Hirahata; Hiroki Hase
Journal:  Clin Exp Nephrol       Date:  2017-04-21       Impact factor: 2.801

8.  Usefulness of an Upright T-Wave in Lead aVR for Predicting the Short-Term Prognosis of Incident Hemodialysis Patients: A Potential Tool for Screening High-Risk Hemodialysis Patients.

Authors:  Ai Matsukane; Toshihide Hayashi; Yuri Tanaka; Masaki Iwasaki; Shun Kubo; Takasuke Asakawa; Yasunori Takahashi; Yoshihiko Imamura; Koichi Hirahata; Nobuhiko Joki; Hiroki Hase
Journal:  Cardiorenal Med       Date:  2015-07-28       Impact factor: 2.041

9.  Myocardial perfusion imaging for predicting cardiac events in Japanese patients with advanced chronic kidney disease: 1-year interim report of the J-ACCESS 3 investigation.

Authors:  Nobuhiko Joki; Hiroki Hase; Yuhei Kawano; Satoko Nakamura; Kenichi Nakajima; Tsuguru Hatta; Shigeyuki Nishimura; Masao Moroi; Susumu Nakagawa; Tokuo Kasai; Hideo Kusuoka; Yasuchika Takeishi; Mitsuru Momose; Kazuya Takehana; Mamoru Nanasato; Shunichi Yoda; Hidetaka Nishina; Naoya Matsumoto; Tsunehiko Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-15       Impact factor: 9.236

10.  Improvement of myocardial fatty acid metabolism by oral nicorandil in hemodialysis patients without coronary artery disease.

Authors:  Masato Nishimura; Yu Okamoto; Toru Takatani; Nodoka Sato; Masaya Nishida; Tetsuya Hashimoto; Satoru Yamazaki; Hiroyuki Kobayashi; Toshihiko Ono
Journal:  J Nephrol       Date:  2014-07-29       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.